Endocrinology of obese and nonobese endometrial cancer patients: is there role of tumor molecular-biological type?

• Published in: Future oncology (London, England) Vol. 15; no. 12; pp. 1335 - 1346
• Main Authors: Berstein, Lev M, Iyevleva, Aglaya G, Ivantsov, Alexander O, Vasilyev, Dmitry A, Poroshina, Tatyana E, Berlev, Igor V
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01-04-2019
• Subjects: Body mass index; endocrine-metabolic features; Endometrial cancer; Health risk assessment; Insulin resistance; molecular-biological types; Mutation; obese and nonobese patients; Obesity; endometrial cancer; endocrine-metabolic features; molecular-biological types; obese and nonobese patients
• ISSN: 1479-6694; 1744-8301
• DOI: 10.2217/fon-2018-0687

To compare endocrine characteristics of endometrial cancer (EC) patients based on recent molecular EC types classification.
A total of 234 treatment-naive EC patients as well their tumors were studied.
Patients with
mutations demonstrated tendency to lower body mass index (BMI) and higher serum estradiol. Patients with p53 overexpression were older and had higher diabetes incidence. In the without characteristic molecular profile group there was no difference in fasting serum insulin, estradiol and testosterone levels between women with BMI ≥30.0 and <30.0. The mismatch repair deficient group patients had a tendency toward later menarche compared with the without characteristic molecular profile group one.
Studied endocrine characteristics are associated with BMI or tumor molecular-biological type that might be relevant to EC genesis, course and prognosis.